Literature DB >> 10580921

Irritable bowel syndrome: a management strategy.

W G Thompson1.   

Abstract

In the development of a management strategy for irritable bowel syndrome (IBS) patients we must consider the great number of people with the condition, most of whom do not consult doctors for it. Furthermore, we must be aware of the hidden agenda of those that do. The cause of IBS is unknown, and consequently cure of this chronic recurrent condition is not likely. Moreover, the disorder is very costly, drawing precious resources from the care of more serious diseases. In this chapter I propose a management strategy based on a firm diagnosis of IBS using a minimum of tests, consideration of the patient's agenda, the use of dietary advice, the strategic use of drugs only in resistant cases, a graded therapeutic response and continuing care. There is no specific treatment. The doctor-patient interaction is most important to allay patients' fears and concerns, assist them with psychosocial difficulties, and provide the caring support known to maximize the 'placebo' effect of any treatment.

Entities:  

Mesh:

Year:  1999        PMID: 10580921     DOI: 10.1053/bega.1999.0039

Source DB:  PubMed          Journal:  Baillieres Best Pract Res Clin Gastroenterol


  12 in total

Review 1.  Recommendations on chronic constipation (including constipation associated with irritable bowel syndrome) treatment.

Authors:  P Paré; Ronald Bridges; Malcolm C Champion; Subhas C Ganguli; James R Gray; E Jan Irvine; Victor Plourde; Pierre Poitras; Geoffrey K Turnbull; Paul Moayyedi; Nigel Flook; Stephen M Collins
Journal:  Can J Gastroenterol       Date:  2007-04       Impact factor: 3.522

Review 2.  Labelling chronic illness in primary care: a good or a bad thing?

Authors:  John Bedson; Rob McCarney; Peter Croft
Journal:  Br J Gen Pract       Date:  2004-12       Impact factor: 5.386

3.  The TRPV1 channel in rodents is a major target for antinociceptive effect of the probiotic Lactobacillus reuteri DSM 17938.

Authors:  Azucena Perez-Burgos; Lu Wang; Karen-Anne McVey Neufeld; Yu-Kang Mao; Mustafa Ahmadzai; Luke J Janssen; Andrew M Stanisz; John Bienenstock; Wolfgang A Kunze
Journal:  J Physiol       Date:  2015-07-20       Impact factor: 5.182

4.  Adequate relief in a treatment trial with IBS patients: a prospective assessment.

Authors:  Maria C F Passos; Anthony J Lembo; Lisa A Conboy; Ted J Kaptchuk; John M Kelly; Mary T Quilty; Catherine E Kerr; Eric E Jacobson; Rong Hu; Elizabeth Friedlander; Douglas A Drossman
Journal:  Am J Gastroenterol       Date:  2009-03-17       Impact factor: 10.864

5.  Validation of irritable bowel syndrome Global Improvement Scale: an integrated symptom end point for assessing treatment efficacy.

Authors:  Susan Gordon; Vanessa Ameen; Barbara Bagby; Britt Shahan; Priti Jhingran; Eric Carter
Journal:  Dig Dis Sci       Date:  2003-07       Impact factor: 3.199

6.  A comparison of irritable bowel syndrome patients managed in primary and secondary care: the Episode IBS study.

Authors:  Graeme D Smith; Douglas T Steinke; Moira Kinnear; Kay I Penny; Nim Pathmanathan; Ian D Penman
Journal:  Br J Gen Pract       Date:  2004-07       Impact factor: 5.386

7.  Functional brain interactions that serve cognitive-affective processing during pain and placebo analgesia.

Authors:  Jason G Craggs; Donald D Price; G Nicholas Verne; William M Perlstein; Michael M Robinson
Journal:  Neuroimage       Date:  2007-08-16       Impact factor: 6.556

8.  The dynamic mechanisms of placebo induced analgesia: Evidence of sustained and transient regional involvement.

Authors:  Jason G Craggs; Donald D Price; William M Perlstein; Nicholas G Verne; Michael E Robinson
Journal:  Pain       Date:  2008-09-19       Impact factor: 7.926

9.  The effect of topical local anesthetics on thermal pain sensitivity in patients with irritable bowel syndrome.

Authors:  Anthony Rodrigues; Christopher D King; Fong Wong; Joseph L Riley; Siegfried Schmidt; Andre P Mauderli
Journal:  Pain Res Treat       Date:  2012-02-28

10.  Do published guidelines for evaluation of irritable bowel syndrome reflect practice?

Authors:  B P Yawn; E Lydick; G R Locke; P C Wollan; S L Bertram; M J Kurland
Journal:  BMC Gastroenterol       Date:  2001-10-26       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.